← Eichor
Study identifier: NCT06125652 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Condition: Acute Myeloid Leukemia Refractory · Acute Myeloid Leukemia, in Relapse  ·  Sponsor: Xuzhou Medical University

PhasePhase 1/Phase 2
Planned participants20
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

This description comes directly from the study's public registry record.

Talk to the study team

Kailin Xu, MD.,PD.  ·  15162166166  ·  lihmd@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Kailin XuXuzhou, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06125652